Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

Completed

• Conditions: Healthy Subjects
• Interventions: Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

• Registration Number: NCT00999271
• Lead Sponsor: Hvidovre University Hospital

Brief Summary

The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Primary Completion: 2009-09
• Study Completion: 2009-09
• Status Verified: 2009-10
• Study First Submitted: 2009-10-20
• Study First Submitted QC: 2009-10-20
• Last Update Submitted: 2009-10-20
• Study First Posted: 2009-10-21
• Last Update Posted: 2009-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• Informed oral and written consent
• Caucasians over the age of 18 years
• Normal 75 g oral glucose tolerance test (OGTT)
• Normal blood haemoglobin concentration
• Normal plasma lipid profile

Exclusion Criteria

• First-degree relatives with diabetes and familial hypertriglyceridemia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthy subjects	Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)	30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine

Trial Locations

Locations (1)

Hvidovre Hospital; 🇩🇰 Hvidovre, Denmark